glp-1 parkinson's disease lancet Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Diseases | CNS Drugs GLP-1 Analogues in the Neurobiology

Platelet rich plasma and the PACKS-4 platelet aggregation instrument was used with the agonists of inducers EPI (final concentration of 200 M), ADP (final concentration of 10.0 M), AA (final concentration of 2.5 g/mL), and collagen (final concentration of 5.0 g/mL)

J Headache Pain 26 , 202 (2025)

Veja que paradoxo: pessoas com obesidade produzem bastante leptina, mas seu organismo resistente a ela ponto para o descontrole mesa

Cardiometabolic Improvements Weight loss was accompanied by clinically meaningful improvements across several cardiovascular risk markers, including reductions in: Waist circumference (mean reduction of approximately 24.1 cm at the highest dose) Non-HDL cholesterol Triglycerides Systolic blood pressure High-sensitivity C-reactive protein (hsCRP) a marker of inflammation These findings are particularly relevant for patients with obesity who also live with cardiometabolic conditions, where systemic risk reduction is as important as the weight loss itself

Gut Fuel for Natural GLP-1 Pathway Support*

So when a clinic implies a slim woman should take a GLP-1 to prevent cancer, they are well out ahead of the evidence